Yusuke Satake trained in pharmaceutical sciences and chemical biology before moving into venture investing through healthcare strategy consulting, and this shows in his backing of technically demanding companies like a migraine treatment app, a microRNA therapeutics developer, a copper-64 radiopharmaceutical platform, and a synthetic biology manufacturing startup. He tends to talk about why a company's science or structure makes sense now, rather than its valuation, and he has also pointed out unusual moves like a stock-for-business acquisition from a large company as a notable shift in how Japanese healthcare startups can grow.
About their Fund
Keio Innovation Initiative was the first impact fund among university-affiliated VCs in Japan, expanding beyond Keio-originated research to back deep-tech startups from other universities and research institutes in fields like regenerative medicine, AI, and health, while building out a formal impact strategy—including a Theory of Change, impact measurement, and shared KPIs with startups—from due diligence through execution. Backed by an unusually large group of investors, including Keio, Nomura, Japan Post Insurance, and major banks and insurers, and led by a CEO with a background spanning journalism, startup operations, and university governance, the fund supports technically complex startups from the lab stage through post-listing, aiming to advance quality of life, social systems, and environmental protection.
















.jpeg)







.jpeg)











































































.png)
























































































































.jpeg)









.jpeg)




















































































